Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-810-4 | CAS number: 7747-35-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1989
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: (guideline, GLP study)
Cross-referenceopen allclose all
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to other study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 989
- Report date:
- 1989
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 83-3 (Prenatal Developmental Toxicity Study)
- Deviations:
- no
- Principles of method if other than guideline:
- None
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 7a-ethyldihydro-1H,3H,5H-oxazolo[3,4-c]oxazole
- EC Number:
- 231-810-4
- EC Name:
- 7a-ethyldihydro-1H,3H,5H-oxazolo[3,4-c]oxazole
- Cas Number:
- 7747-35-5
- Molecular formula:
- C7H13NO2
- IUPAC Name:
- 7a-ethyl-tetrahydro-1H-[1,3]oxazolo[3,4-c][1,3]oxazole
- Details on test material:
- - Name of test material (as cited in study report): BIOBANTM CS-1246 Antimicrobial
- Physical state: Clear, colorless liquid
- Analytical purity: Assumed to be 100% pure
- Lot/batch No.: 14400, 14401, 14402, 14403
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Breeding Laboratories, INC. (Portage, MI, USA)
- Age at study initiation:81 days of age
- Weight at study initiation: Approximately 217-273 grams on gestation day 0
- Housing: All animals were housed indiviually housed in clean, wire-mesh cages suspended above cage board.
- Diet (ad libitum): Animals were supplied by diet of Purina certified Rodent Chow# 5002 in block form.
- Water (ad libitum): Tap water was provided to animals.
- Acclimation period: 10 days
ENVIRONMENTAL CONDITIONS
- Temperature (°F): 69°F-75°F
- Humidity (%): 54-82%
- Air changes (per hr): 10-15
- Photoperiod: (12 hrs dark / 12 hrs light
Administration / exposure
- Route of administration:
- oral: gavage
- Type of inhalation exposure (if applicable):
- other: Not applicable
- Vehicle:
- other: Deionized water
- Details on exposure:
- Preparation: The approprate amount of test article, AMINE CS-1246, for each group was weighed into 500 ml volumetric flasks. The flask was brought to volume with deionized water. The solution was inverted and shaken untill the test material was dissolved. The solution was transferred to a storage container and sufficient amount of vehicle was added to attain the appropriate concentration. Solutions for all dose groups were prepared weekly.
Administration: The test mixtures were administered orally by gavage, via a 16-gauge stainless stell gavage canula, once daily for 10 consecutive days initiating on gestation day 6 and continuing up to and including day 15 gestation. A dosage volume of 10 ml/kg was used for all dose levels.The control animals received 10 ml/kg deionized water on the same regimen. Indiviual dosages were based on the most recent body weights to provide correct mg/kg/dose. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- See attachment-1 for details of dosing solution analysis.
Concentration inj vehicle: 0, 5, 25, 65 mg/mL - Details on mating procedure:
- Length of mating period not specified. Females were placed in the home cages of the males until positive indication of mating was observed (presence of copulatory plug or a vaginal smear positive for sperm).
- Duration of treatment / exposure:
- Days 6 through 15 of gestation
- Frequency of treatment:
- Once daily
- Duration of test:
- 20 days
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
50 mg/kg/day
Basis:
nominal conc.
- Remarks:
- Doses / Concentrations:
250 mg/kg/day
Basis:
nominal conc.
- Remarks:
- Doses / Concentrations:
650 mg/kg/day
Basis:
nominal conc.
- No. of animals per sex per dose:
- 25 animals/group
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Dose levels were selected based on the results of preliminary range finding study (WIL-129006)
- Rationale for animal assignment: random)
Examinations
- Maternal examinations:
- Body weights were recorded on gestation days 0, 6, 9, 12, 16, and 20. Animals were observed twice daily from days 0-20 of gestation. They were observed for signs of toxicity at the time of dosing and approximately one hour following dosing.No indications that food consumption was recorded.
- Ovaries and uterine content:
- The uterus was opened and the total number and location of all fetuses, early and late resorptions, and total number of implantation sites were recorded. The individual uterine distribution of implantation sites was documented. Uteri with no macroscopic evidence of nidation were excised, opened, and placed in ammonium sulfide solution for detection of early implantation loss.
- Fetal examinations:
- - External examinations: Yes: Fetuses were weighed, sexed, and tagged for identification.
- Soft tissue examinations: Yes: on approximately half of the fetuses
- Skeletal examinations: Yes: on approximately half of the fetuses
A detailed external examination of each fetus was conducted on the eyes, palate, and external orifices. Crown-rump length was recorded for late resorptions. Approximately half of the fetuses underwent a soft tissue examination, and the other half a skeletal examination. External, visceral, and skeletal findings were recorded as developmental variations or malformations. - Statistics:
- All analyses were conducted using two-tailed tests for minimum significance levels of 5% comparing the treatment group to the control group. All group means were presented with standard deviations. Fetal sex ratios were compared by the chi-square test with Yates' correction factor. The numbers of litters with malformations and variations were compared by Fisher's exact test. The numbers of early and late resorptions, dead fetuses, and postimplantation losses were compared by the Mann-Whitney U-test. Mean numbers of corpora lutea, total implantations, viable fetuses, mean fetal body weights, maternal body weights, maternal body weights at each interval, maternal body weight gains, and food consumption were analyzed by a one-way ANOVA and Dunnett's test.
- Indices:
- None
- Historical control data:
- None
Results and discussion
Results: maternal animals
Maternal developmental toxicity
- Details on maternal toxic effects:
- Maternal toxic effects:no effects
Details on maternal toxic effects:
Survival of the dams was 100% in all dose groups. The incidence of clinical findings did not suggest a relationship to test material administration. Mean maternal body weights were depressed in animals dosed with 650 mg/kg/day. No adverse effect on maternal body weights was seen at dose levels of 50 and 250 mg/kg/day. There were no treatment-related necropsy findings noted at any dose level.
Effect levels (maternal animals)
- Dose descriptor:
- NOAEL
- Effect level:
- 250 other: mg/kg bw
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
Results (fetuses)
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
Details on embryotoxic / teratogenic effects:
Eighteen fetuses (in four litters) in the 650 mg/kg/day group had malformations. The majority of the malformations were abdominal wall defects and/or cleft palate, and were clustered in 2 litters. Two of the three late resorptions in an additional litter had similar malformations. Mean fetal weight was slightly decreased in the 650 mg/kg/day group when compared to controls (although within the historical control range). An increase in the percentage of fetuses with delayed ossification of sternebrae 5 and 6 was observed in both the high and the low dose group as compared to controls. These finding were within historical control values and there was no dose-reponse relationship. No other signs of embryotoxicity or fetotoxicity were apparent at any dose level.
Effect levels (fetuses)
- Dose descriptor:
- NOAEL
- Effect level:
- 250 other: mg/kg bw
- Based on:
- test mat.
- Basis for effect level:
- other: teratogenicity
Fetal abnormalities
- Abnormalities:
- not specified
Overall developmental toxicity
- Developmental effects observed:
- not specified
Any other information on results incl. tables
Survival
of the dams was 100% in all dose groups. The
incidence of clinical findings did not suggest a relationship to test
material administration. Mean
maternal body weights were severely depressed in animals dosed with 650
mg/kg/day. No
adverse effect on maternal body weights was seen at dose levels of 50
and 250 mg/kg/day. There
were no treatment-related necropsy findings noted at any dose level.
Eighteen fetuses (in four litters) in the 650 mg/kg/day group had
malformations. The
majority of the malformations were abdominal wall defects and/or cleft
palate, and were clustered in 2 litters. Two
of the three late resorptions in an additional litter had similar
malformations. Mean
fetal weight was slightly decreased in the 650 mg/kg/day group when
compared to controls (although within the historical control range); the
decrease was due mainly to the two litters with most of the malformed
fetuses. An
increase in the percentage of fetuses with delayed ossification of
sternebrae 5 and 6 was considered biologically-relevant at the high dose.
No
fetal anomalies were noted in the 50 and 250 mg/kg/day groups.
The
incidence of fetal and developmental variations in the 50 and 250
mg/kg/day groups was comparable to those in the concurrent control group
and in the historical control data of the testing facility.
No
other signs of embryotoxicity or fetotoxicity were apparent at any dose
level.
The
NOAEL was reported to be 250 mg/kg/day.
Applicant's summary and conclusion
- Conclusions:
- In conclusion, a dose level of 650 mg/kg/day caused maternal toxicity and developmental toxicity. However, this developmental toxicity was characterized by marked interlitter differences in suseptibility.THE NOAEL in this study was 250 mg/kg/day.
- Executive summary:
Virgin female Crl:CD BR rats were dosed by oral gavage an aqueous solution of the test material daily from gestation day 6-15. Animals were observed twice daily from days 0-20 of gestation. They were observed for signs of toxicity at the time of dosing and approximately one hour following dosing. Body weights were recorded on gestation days 0, 6, 9, 12, 16, and 20.
Each surviving female was sacrificed on gestation day 20 and examined for gross abnormalities. The number of corpora lutea on each ovary was counted. The uterus was opened and the total number and location of all fetuses, early and late resorptions, and total number of implantation sites were recorded. The individual uterine distribution of implantation sites was documented. Uteri with no macroscopic evidence of nidation were excised, opened, and placed in ammonium sulfide solution for detection of early implantation loss.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.